公司概述
Carlsmed, Inc. operates as a commercial-stage medical technology company dedicated to designing, manufacturing, and marketing AI-enabled personalized solutions specifically for spine surgery. The enterprise functions within the Healthcare sector, specifically targeting the Health Information Services industry, where it leverages proprietary technology to facilitate spine fusion surgery procedures through its comprehensive platform, aprevo. The company's current market capitalization stands at $259.83M, supported by an annual revenue of $50.51M and a workforce comprising 127 employees. These valuation and revenue figures indicate that Carlsmed positions itself as a mid-cap entity in a specialized niche, reflecting significant investor interest relative to its physical scale and revenue generation capabilities.
财务健康
The company reported a trailing twelve-month revenue of $50.51M, yet this revenue generated a net income loss of $-30,218,000 and an EBITDA of $-30,293,000, revealing a cost structure where expenses heavily outweigh operational earnings before interest and taxes. The free cash flow stands at $-21,646,500, which signifies that the company is burning cash and lacks the current financial flexibility to fund operations entirely from internal cash generation without external capital support. Profitability metrics are constrained by a gross margin of 75.3%, which is healthy for a technology firm, but this is eroded by an operating margin of -61.4% and a profit margin of -58.7%, indicating substantial overhead costs or investment in growth that have not yet translated to net profit. Despite the earnings deficit, the balance sheet remains robust with $109.79M in cash against $17.41M in debt, though the high debt-to-equity ratio of 17.61 suggests a leveraged capital structure rather than a conservative one. Liquidity is exceptionally strong as evidenced by a current ratio of 8.87, implying the company holds ample short-term assets to cover its immediate obligations. Return metrics show a return on equity of -47.6% and a return on assets of -21.0%, revealing that management is currently unable to generate positive returns on the capital base due to the ongoing operational losses.
估值评估
Valuation multiples present a complex picture with a trailing P/E ratio of N/A and a forward P/E of -6.55, implying that the market is pricing in significant expected earnings improvement or is utilizing alternative metrics due to current losses. The price-to-book ratio of 2.62 suggests the market is valuing the company at a 162% premium over its book value, potentially reflecting confidence in its intangible assets and technology platform. Alternative valuation metrics such as a price-to-sales ratio of 5.14 and an EV/EBITDA of -5.53 further illustrate that the stock is priced based on sales growth expectations rather than current profitability. The stock's trading range over the last year spans from a low of $8.87 to a high of $17.19; without a specific current price provided in the facts, the precise location within this range cannot be calculated, but the wide spread indicates significant price volatility. The beta value is listed as N/A, meaning that the historical volatility relative to the broader market is not quantifiable in the available data, making it difficult to gauge systematic risk compared to the overall market index.
Growth & Income
Revenue growth accelerated significantly with a year-over-year increase of 61.2%, while earnings growth is N/A due to the company's ongoing losses, indicating that top-line expansion is currently outpacing any potential for earnings recovery. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which confirms that all available capital is being reinvested into the business for growth rather than distributed to shareholders. This reinvestment strategy is typical for early-stage or growth-oriented medical technology firms that prioritize scaling their AI-enabled platform over returning cash to investors. The overall growth and income profile characterizes Carlsmed as a high-risk, high-revenue-growth opportunity that offers no current income stream, relying entirely on future operational success to justify its current market valuation.